Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular biology reports"
DOI: 10.1007/s11033-022-07280-w
Abstract: BACKGROUND Obinutuzumab, a Type II anti-CD20 antibody, is used to treat follicular lymphoma. A major mode of action of obinutuzumab is antibody-dependent cellular cytotoxicity (ADCC). Knowledge of the mechanisms of resistance to obinutuzumab is important… read more here.
Keywords: combination; obinutuzumab induced; antibody dependent; resistance ... See more keywords